RLAY
Relay Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$19.04
+0.16%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.40
- Revenue estimate
- $1.6M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.41
- EPS estimate
- -$0.39
- Revenue actual
- $350.0K
- Revenue estimate
- $960.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -4.0%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $29
- PT range
- $26 – $31
- Analysts
- 6
6 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026